Biotech News

IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

Immutep Limited (IMMP)Immutep LimitedCompany update

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced positive data from its Phase I study of IMP761, its first-in-class LAG-3 agonist antibody, from a late-breaking abstract at ACR Convergence 2026 in Orlando, Florida. ACR Convergence is the annual scientific meeting of the American College of Rheumatology.

Related news

IMMPImmutep Limited2026-11-10 23:02 EST

Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO

IMMPImmutep Limited2026-11-19 00:12 EST

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

FATEFate Therapeutics2026-11-10 12:00 EST

Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy

REGNRegeneron Pharmaceuticals2026-11-19 12:00 EST

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)

BMEABiomea Fusion2026-11-10 21:05 EST

Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights

LEGNLegend Biotech Corporation2026-11-10 12:00 EST

Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights

GPCRStructure Therapeutics2026-11-09 21:05 EST

Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

IMCRImmunocore Holdings plc2026-10-29 13:00 EST

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Immutep Limited

Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.

Recent company news

Stock data

Close
3.42 USD
Market cap
61.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States